CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells

RhoB Mediates Phosphoantigen Recognition by Vγ9Vδ2 T Cell Receptor

(2016) Zsolt Sebestyen et al.   Cell Reports

HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity

(2015) Matthias Peipp et al.   Oncotarget

Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30

(2015) Christian Kellner et al.   OncoImmunology

Effect of NKG2D ligand expression on host immune responses

(2015) Marine Champsaur et al.   IMMUNOLOGICAL REVIEWS

Butyrophilin 3A1 binds phosphorylated antigens and stimulates human γδ T cells

(2013) Stefano Vavassori et al.   NATURE IMMUNOLOGY

Human Vδ2 versus non-Vδ2 γδ T cells in antitumor immunity

(2013) Dieter Kabelitz et al.   OncoImmunology

Tumor cell recognition by γδ T lymphocytes

(2013) Daniel V. Correia et al.   OncoImmunology

Dysfunctional V 9V 2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells

(2012) M. Coscia et al.   BLOOD

Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human    T-cell subset

(2012) C. Harly et al.   BLOOD

Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside

(2012) Mounia S. Braza et al.   BRITISH JOURNAL OF HAEMATOLOGY

Mimicking an Induced Self Phenotype by Coating Lymphomas with the NKp30 Ligand B7-H6 Promotes NK Cell Cytotoxicity

(2012) C. Kellner et al.   JOURNAL OF IMMUNOLOGY

Harnessing γδ T cells in anticancer immunotherapy

(2012) Dalil Hannani et al.   TRENDS IN IMMUNOLOGY

Human kappa light chain targeted Pseudomonas exotoxin A — identifying human antibodies and Fab fragments with favorable characteristics for antibody–drug conjugate development

(2011) C. Kellner et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity

(2011) C Kellner et al.   LEUKEMIA

Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells

(2011) S Stamova et al.   LEUKEMIA

Crystal structure of a    T-cell receptor specific for the human MHC class I homolog MICA

(2011) B. Xu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Human    T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement

(2010) A. Maniar et al.   BLOOD

Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vγ9Vδ2 T lymphocyte agonist in patients with solid tumors

(2010) Jaafar Bennouna et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

NKG2D Costimulates Human V 9V 2 T Cell Antitumor Cytotoxicity through Protein Kinase C -Dependent Modulation of Early TCR-Induced Calcium and Transduction Signals

(2010) S. Nedellec et al.   JOURNAL OF IMMUNOLOGY

The NKG2D ligand ULBP4 binds to TCR 9/ 2 and induces cytotoxicity to tumor cells through both TCR   and NKG2D

(2009) Y. Kong et al.   BLOOD

Natural killer and γδ T cells in haematological malignancies: enhancing the immune effectors

(2009) Jérôme Rey et al.   TRENDS IN MOLECULAR MEDICINE

Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

(2008) Jaafar Bennouna et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Isopentenyl Pyrophosphate-Activated CD56+    T Lymphocytes Display Potent Antitumor Activity toward Human Squamous Cell Carcinoma

(2008) A. A.Z. Alexander et al.   CLINICAL CANCER RESEARCH

NKG2D ligands in tumor immunity

(2008) N Nausch et al.   ONCOGENE